The lab announced first-patient dosing in a new early-phase vaccine study designed to train the immune system to produce protective antibodies. The trial will evaluate immune response strength, dosing strategies, and overall safety profile.

This research reflects a broader shift toward immunology-driven drug development and advanced biologic therapies. Global clinical trial pipelines increasingly focus on vaccines and immune-modulating therapies for chronic and infectious diseases.

Researchers believe the study could support future multi-stage vaccine development and help accelerate protective therapies for high-burden diseases worldwide.